Literature DB >> 16318752

[Microkeratome-assisted lamellar keratoplasty for recurrent corneal granular dystrophy after phototherapeutic keratectomy].

Wei Chen1, Guo-xing Li, Qin-mei Wang, Yun-e Zhao, Jia Qu.   

Abstract

OBJECTIVE: To evaluate the safety and efficacy of microkeratome-assisted lamellar keratoplasty (MLK) for the treatment of recurrent granular corneal dystrophy (GCD) after phototherapeutic keratectomy (PTK).
METHODS: We performed a prospective study of nine eyes (seven patients) with recurrent granular dystrophy after PTK. A microkeratome was used to cut partial-thickness sections through the anterior surface of the donor and host corneas. The donor disc was placed on the recipient bed with four or eight interrupted sutures. The stitches were removed between 4 and 6 weeks after surgery. Visual acuity (VA), corneal clarity, corneal thickness, and corneal topography were assessed before and at different time points after surgery.
RESULTS: During a mean follow-up period of (18.9 +/- 4.1) months, all grafts were transparent without visible opacity at the interface, and no serious complications occurred. The VA was improved in all cases. seven eyes had best corrected visual acuity with spectacles of 20/40 or better, two eyes reached 20/25. At the last follow-up visit more than 12 months postoperatively, the mean corneal refractive power increased significantly by (2.34 +/- 0.93) D (P < 0.01), and the corneal astigmatism significantly decreased by (0.91 +/- 0.98) D (P < 0.05). The mean corneal thickness was (477.4 +/- 26.9) microm preoperatively and (507.8 +/- 23.4) microm at the last follow-up visit (P < 0.01).
CONCLUSIONS: Our findings suggest that MLK for the treatment of recurrent GCD is a safe and easy-to-perform method for restoring VA.

Entities:  

Mesh:

Year:  2005        PMID: 16318752

Source DB:  PubMed          Journal:  Zhonghua Yan Ke Za Zhi        ISSN: 0412-4081


  1 in total

Review 1.  [Keratoplasty: laminate or penetrate? Part 2: lamellar keratoplasty].

Authors:  P Maier; T Reinhard
Journal:  Ophthalmologe       Date:  2009-07       Impact factor: 1.059

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.